文献速递淋巴瘤造血干细胞移植与细胞治疗

淋巴瘤患者接受高剂量化疗联合自体干细胞移植后的心血管疾病:一项丹麦人群研究

Cardiovascular diseases after high-dose chemotherapy and autologous stem cell transplant for lymphoma: A Danish population-based study.
PubMed 文献 · Br J Haematol · 2023-12-28

该丹麦人群研究纳入2001至2017年间接受HDT-ASCT的侵袭性淋巴瘤患者787例,按1:5匹配一般人群,中位随访7.6年。

要点

  • 10年CHF累积发生率HDT-ASCT组8.0%,匹配对照组2.0%(P<0.001)。
  • 男性、≥2线治疗、高血压和蒽环类累积剂量≥300 mg/m2为CHF危险因素。

核心结论

  • HDT-ASCT与充血性心力衰竭及其他心脏疾病风险升高相关,研究结果可用于HDT-ASCT与新型疗法的获益/风险评估。

研究设计与样本

  • 丹麦人群研究,纳入2001至2017年间接受HDT-ASCT的侵袭性淋巴瘤患者787例,按性别、出生年份和Charlson合并症评分1:5匹配一般人群,通过全国登记系统捕获事件。
  • 另设4089例淋巴瘤患者队列,将HDT-ASCT作为时间依赖暴露进行分析。

主要发现

  • 10年充血性心力衰竭累积发生率HDT-ASCT组8.0% vs 匹配对照组2.0%(P<0.001)。
  • 男性、≥2线治疗、高血压和蒽环类累积剂量≥300 mg/m2为充血性心力衰竭的危险因素。
  • HDT-ASCT亦增加其他心脏疾病的风险。

临床怎么用

  • 原文指出,这些发现可用于HDT-ASCT与新型疗法的获益/风险评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cardiovascular diseases, especially congestive heart failure (CHF), are known complications of anthracyclines, but the risk for patients undergoing high-dose chemotherapy and autologous stem cell transplant (HDT-ASCT) is not well established. With T-cell therapies emerging as alternatives, studies of long-term complications after HDT-ASCT are warranted. Danish patients treated with HDT-ASCT for aggressive lymphoma between 2001 and 2017 were matched 1:5 on sex, birth year and Charlson comorbidity score to the general population. Events were captured using nationwide registers. A total of 787 patients treated with HDT-ASCT were identified. Median follow-up was 7.6 years. The risk of CHF was significantly increased in the HDT-ASCT population compared to matched comparators with an adjusted hazard ratio (HR) of 5.5 (3.8-8.1). The 10-year cumulative incidence of CHF was 8.0% versus 2.0% (p < 0.001). Male sex, ≥2 lines of therapy, hypertension and cumulative anthracycline dose (≥300 mg/m2 ) were risk factors for CHF. In a separate cohort of 4089 lymphoma patients, HDT-ASCT was also significantly associated with increased risk of CHF (adjusted HR of 2.6 [1.8-3.8]) when analysed as a time-dependent exposure. HDT-ASCT also increased the risk of other cardiac diseases. These findings are applicable for the benefit/risk assessment of HDT-ASCT versus novel therapies.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Baech J, Husby S, Trab T, et al. Cardiovascular diseases after high-dose chemotherapy and autologous stem cell transplant for lymphoma: A Danish population-based study. Br J Haematol. 2023. PMID: 38155503. doi:10.1111/bjh.19272

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。